{"entity":{"id":"jbs-003","kind":"drug","name":"F-MISO (JBS-003)","aka":["JBS-003","F-MISO","18F-FMISO","[18F]fluoromisonidazole","fluorine-18 fluoromisonidazole"],"tldr":"F-MISO (JBS-003) is an experimental radiopharmaceutical PET imaging agent from Juniper Biosciences, in phase 3 trials for HPV-positive oropharyngeal cancer and HPV-positive head and neck cancer.","summary":"F-MISO (JBS-003) (JBS-003, F-MISO, 18F-FMISO) is a radiopharmaceutical PET imaging agent (diagnostic) from Juniper Biosciences, with Memorial Sloan Kettering Cancer Center as partner. A fluorine-18 PET tracer that becomes trapped in oxygen-starved tumour cells; FMISO PET is used to pick out HPV-positive throat cancer patients whose tumours are not hypoxic and who may safely receive lower-dose radiation. Its furthest stage is phase 3, for HPV-positive oropharyngeal cancer and HPV-positive head and neck cancer. ClinicalTrials.gov registers it in 3 studies linked below. FDA Breakthrough Therapy designation reported by MSK (page updated September 2026). Phase 3 NCT06563479 recruiting, sponsored by Memorial Sloan Kettering. Whether it works in people has not been established unless a trial below reports it.","status":"phase-3","asOf":"2026-11-03","links":[{"label":"Juniper Biosciences: web.archive.org","url":"https://web.archive.org/web/20260713121640/https://juniperbiosci.com/pipeline/"},{"label":"Juniper Biosciences: web.archive.org","url":"https://web.archive.org/web/20260713121640/https://juniperbiosci.com/pipeline/"},{"label":"Juniper Biosciences: mskcc.org","url":"https://www.mskcc.org/news/low-dose-radiation-possible-game-changer-treating-hpv-positive-head-and-neck"},{"label":"Juniper Biosciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06563479"},{"label":"ClinicalTrials.gov: trials of JBS-003","url":"https://clinicaltrials.gov/search?intr=JBS-003"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["hpv-positive-oropharyngeal-cancer","oropharyngeal-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["juniper-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06563479","nct05491512","nct06984861"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"JBS-003","modality":"Radiopharmaceutical PET imaging agent (diagnostic)","mechanism":"A fluorine-18 PET tracer that becomes trapped in oxygen-starved tumour cells; FMISO PET is used to pick out HPV-positive throat cancer patients whose tumours are not hypoxic and who may safely receive lower-dose radiation.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/jbs-003/","neighbours":{"cancer":[{"id":"hpv-positive-oropharyngeal-cancer","kind":"cancer","name":"HPV-positive oropharyngeal cancer","route":"/cancers/hpv-positive-oropharyngeal-cancer/"},{"id":"oropharyngeal-cancer","kind":"cancer","name":"Oropharyngeal cancer (tonsil and base of tongue)","route":"/cancers/oropharyngeal-cancer/"}],"company":[{"id":"juniper-biosciences","kind":"company","name":"Juniper Biosciences","route":"/companies/juniper-biosciences/"}],"trial":[{"id":"nct06563479","kind":"trial","name":"A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer","route":"/trials/nct06563479/"},{"id":"nct05491512","kind":"trial","name":"A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer","route":"/trials/nct05491512/"},{"id":"nct06984861","kind":"trial","name":"A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer","route":"/trials/nct06984861/"}]}}